Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
28
10
2021
accepted:
25
01
2022
revised:
20
01
2022
pubmed:
19
2
2022
medline:
28
7
2022
entrez:
18
2
2022
Statut:
ppublish
Résumé
Metaplastic breast carcinomas are a rare and heterogeneous group of tumors (0.5-2%). They are mainly triple negative tumors but they present poorer chemotherapy responses and worse prognosis than other triple negative tumors. The aim of our study was to characterize the molecular profile and tumor evolution in matched (primary-relapse) tumor samples from patients with early-stage metaplastic breast carcinomas who had disease recurrence/progression. We performed genomic profiling of tumor biopsies at least from two different time points of their tumor evolution. Tumor samples were analyzed by DNA-Next Generation Sequencing (Illumina 2 x 75bp) using the Action OncoKitDX panel (Imegen-Health in Code group), which includes point mutations in 50 genes, CNVs, and fusion genes. Only pathogenic and likely pathogenic variants were considered for analysis and they were categorized following the ComPerMed criteria. We analyzed 21 matched tumor samples (8 primary and 13 relapse/progression samples). Genomic profiling of matched tumor samples revealed that mutations present in primary tumors are generally maintained in the relapse/disease progression. We did not find a significant increase in point mutations between primary and relapse/progression samples, although gene amplifications were found more frequently in relapse/progression samples. Tumor samples harbored high frequency of TP53 (100%) and TERT promoter (29%) mutations, and of MYC amplifications (80% of which in relapse/progression samples). No PI3KCA mutations were found, but PTEN variations were enriched in 38% of samples (10% mutations and 28% deletions). FGFR1 amplifications were identified in 13% of samples (primary tumor only). Neither ERBB2 nor EGFR gene amplifications were detected. The most frequent pathogenic alterations occurred in cycle regulation's genes, including TP53 and TERT promoter mutations, and MYC amplifications. Relapse/progression samples were highly enriched for MYC amplification. Larger studies are required to better characterize these tumors, and identify new strategies to improve the prognosis of these patients.
Identifiants
pubmed: 35177782
doi: 10.1038/s41379-022-01017-7
pii: S0893-3952(22)00099-0
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1066-1074Informations de copyright
© 2022. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
Références
Pezzi, C. M. et al. Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the national cancer data base. Ann. Surg. Oncol. 14, 166–173 (2007).
doi: 10.1245/s10434-006-9124-7
Weigelt, B., Eberle, C., Cowell, C. F., Ng, C. K. Y. & Reis-Filho, J. S. Metaplastic breast carcinoma: More than a special type. Nat. Rev. Cancer 14, 147–148 (2014).
doi: 10.1038/nrc3637
Zhu, L. & Chen, K. Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: An NCDB analysis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. BMC Cancer 19, 1–9 (2019).
doi: 10.1186/s12885-018-5219-3
Moreno, A. C. et al. Outcomes after treatment of metaplastic versus other breast cancer subtypes. J. Cancer 11, 1341–1350 (2020).
doi: 10.7150/jca.40817
Lakhani SR El, Schnitt S. J., Tan P. H., van de V. M., WHO Classification of Tumours of the Breast. WHO Press, 2012
Tan, P. H. et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology 77, 181–185 (2020).
doi: 10.1111/his.14091
Rayson, D., Adjei, A. A., Suman, V. J., Wold, L. E. & Ingle, J. N. Metaplastic breast cancer: Prognosis and response to systemic therapy. Ann. Oncol. 10, 413–419 (1999).
doi: 10.1023/A:1008329910362
Han, M. L. et al. Metaplastic breast carcinoma: A clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy. Mod. Pathol. 32, 807–816 (2019).
doi: 10.1038/s41379-019-0208-x
Bodo, M., Dobrossy, L., Rahoty, P. & Daubner, K. Diagnosis of carcinoma of the breast by aspiration biopsy cytology. Arch. Geschwulstforsch 47, 624–626 (1977).
pubmed: 606197
Hennessy, B. T. et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69, 4116–4124 (2009).
doi: 10.1158/0008-5472.CAN-08-3441
Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl Acad. Sci. USA 107, 15449–15454 (2010).
doi: 10.1073/pnas.1004900107
Steinestel, K., Eder, S., Schrader, A. & Steinestel, J. Clinical significance of epithelial-mesenchymal transition. Clin. Transl. Med. 3, 17 (2014).
doi: 10.1186/2001-1326-3-17
Ng, C. K. Y. et al. The landscape of somatic genetic alterations in metaplastic breast carcinomas. Clin. Cancer Res. 23, 3859–3870 (2017).
doi: 10.1158/1078-0432.CCR-16-2857
González-Martínez, S. et al. Palacios J Molecular features of metaplastic breast carcinoma: An infrequent subtype of triple negative breast carcinoma. Cancers 12, 1–13 (2020).
doi: 10.3390/cancers12071832
Cancer LIA for R on (2019) WHO Classification of Tumors Editorial Board, ed. WHO classification of tumors, 5th edition– Breast tumors.
Martínez-Fernández, P. et al. Comprehensive NGS panel validation for the identification of actionable alterations in adult solid tumors. J. Pers. Med. 11, 1–15 (2021).
doi: 10.3390/jpm11050360
Krings, G. & Chen, Y. Y. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma. Mod. Pathol. 31, 1661–1674 (2018).
doi: 10.1038/s41379-018-0081-z
Afkhami, M. et al. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS One 14, 1–12 (2019).
doi: 10.1371/journal.pone.0224726
McCart Reed, A. E. et al. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. J. Pathol. 247, 214–227 (2019).
doi: 10.1002/path.5184
Reddy, T. P. et al. A comprehensive overview of metaplastic breast cancer: Clinical features and molecular aberrations. Breast Cancer Res. 22, 1–11 (2020).
doi: 10.1186/s13058-019-1178-0
Shimoi, T. et al. TERT promoter hotspot mutations in breast cancer. Breast Cancer 25, 292–296 (2018).
doi: 10.1007/s12282-017-0825-5
Nault, J. C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 1–6 (2013).
doi: 10.1038/ncomms3218
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 5, 405–424 (2015).
doi: 10.1038/gim.2015.30
Tray, N., Taff, J. & Adams, S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat. Rev. 79, 101878 (2019).
doi: 10.1016/j.ctrv.2019.08.004
Fallah, Y., Brundage, J., Allegakoen, P. & Shajahan-Haq, A. N. MYC-Driven pathways in breast cancer subtypes. Biomolecules 7, 1–6 (2017).
doi: 10.3390/biom7030053
Reis-filho, J. S. et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 209, 445–453 (2006).
doi: 10.1002/path.2004
Gilbert, J. A. et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol. Cancer Ther. 4, 944–951 (2008).
doi: 10.1158/1535-7163.MCT-07-0570
Vendrell, J. A. et al. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res. 72, 3593–3606 (2012).
doi: 10.1158/0008-5472.CAN-11-3095
Littlepage, L. E. et al. The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2, 638–651 (2012).
doi: 10.1158/2159-8290.CD-12-0093
Bellanger, A. et al. The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone. J. Pathol. 242, 73–89 (2017).
doi: 10.1002/path.4882
Hayes, M. J., Thomas, D., Emmons, A., Giordano, T. J. & Kleer, C. G. Human cancer biology genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin. Cancer Res. 14, 4038–4045 (2008).
doi: 10.1158/1078-0432.CCR-07-4379